Funding Opportunity PAR-20-253 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Funding Opportunity RFA-CA-20-037 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Notice NOT-MH-20-034 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-20-251 from the NIH Guide for Grants and Contracts. The purpose of this Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Through this award program, promising predoctoral students will obtain individualized, mentored research training from outstanding faculty sponsors while conducting well-defined research projects in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) does not allow candidates to propose to lead an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Notice NOT-AI-20-058 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-019 from the NIH Guide for Grants and Contracts

Notice NOT-AT-20-018 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-059 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-082 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Head of Research Location: EMBL- Cambridge, Cambridgeshire, England

Notice NOT-AR-20-020 from the NIH Guide for Grants and Contracts

Notice NOT-AG-20-042 from the NIH Guide for Grants and Contracts

£31,350 to £32,315 per annum: Rothamsted Research: We are seeking an enthusiastic Bioinformatics Scientist to contribute to a large cross-institute research program called Designing Future Wheat (DFW). EX20 2SB, Okehampton

£44,954 to £53,850: Wellcome Sanger Institute: An opportunity for a Principal Bioinformatician to provide computational support to our cutting-edge science within Open Targets. Hinxton, Saffron Walden, Essex

Effectively communicate analysis results to development teams. This position will involve cross-functional teamwork to build and develop bioinformatics tools…
From Seattle Genetics - Fri, 03 Jul 2020 06:15:17 GMT - View all Bothell, WA jobs

Internal stakeholders may include Clinical Pharmacologists, Biomarker & Bioinformatics scientists, Clinical Project Managers and others.
From Seattle Genetics - Fri, 03 Jul 2020 06:15:17 GMT - View all Bothell, WA jobs

Notice NOT-OD-20-139 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-20-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to invite applications from multidisciplinary teams for the development of metabolomics-based dietary intake biomarkers and validate them against current benchmark dietary biomarkers and dietary assessment approaches.

Funding Opportunity RFA-DK-20-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications under U24 mechanism for a Data Coordination Center to participate and coordinate in a dietary biomarker development study. A companion FOA (RFA DK-20-005), Biomarkers of Dietary Intake and Exposure (U2C Clinical Trial Required) invites multidisciplinary teams to discover, develop and validate dietary biomarkers of intake of wide range of food groups and food types and evaluate the performance of these markers and compare them with dietary assessment methodologies and other benchmark predictive markers.

Funding Opportunity RFA-HD-21-020 from the NIH Guide for Grants and Contracts. The purpose of the Non-invasive Diagnostics in Gynecologic Health RFA is to support SBIR projects to small businesses using advanced technologies (e.g., bio-chips, microfluidics, and mobile technologies) to develop novel or improved diagnostic and/or screening approaches, tools, or devices for endometriosis, adenomyosis, and/or uterine fibroids. The ultimate goal of the program is to improve human gynecologic health by fostering partnerships between small businesses and experts in diverse fields of research to commercialize approaches that improve accuracy and decrease the delay in diagnosis and/or screening of the named gynecologic conditions. These projects will also encourage collaborations with investigators and small businesses who have not yet applied their expertise to gynecologic research, thereby expanding the potential scientific insight and investigational toolkit available to these projects. It is anticipated that, through rigorous collaborative R and D efforts, safe and effective techniques, instruments, and devices can be developed for use in the evaluation and diagnosis of women with endometriosis, uterine fibroids, or adenomyosis. Within the disorders noted above, projects that address a specific and well-characterized clinical need will be considered of high potential impact. The technologies developed with funding through this FOA are expected to be integrated systems or, if they are novel components, to be easily integrated into existing systems. Some other technical features that are expected are the following: reliability, robustness, safety, simplicity, reliance on the appropriate baseline information, contextual awareness, and inclusion of software to support decision-making where appropriate. Proposed tools and technologies should incorporate existing standards and consider regulatory requirements where appropriate. In addition, improved access to underserved areas, and cost-effectiveness should be highlighted.